Abstract
Irinotecan, a topoisomerase I inhibitor, is an effective agent for non-small-cell lung cancer (NSCLC). To determine the efficacy and toxicity of irinotecan and carboplatin, we conducted a phase II study in 61 patients with advanced NSCLC. Every 4 weeks, the patients received irinotecan 50 mg/m2 (days 1, 8 and 15) and carboplatin (day 1) with a target AUC of 5 mg min/ml using the Chatelut formula. All patients were evaluable for toxicity, and of 59 patients evaluable for response, 20 achieved a partial response and 26 showed no change. The overall response rate was 34% (95% confidence interval 23-48%). Grade 3 or 4 anemia, leukopenia, neutropenia, thrombocytopenia and diarrhea occurred in 32%, 32%, 60%, 25%, and 7%, respectively. The median survival time and 1-year, and 2-year survival rates were 10.0 months, 37.6%, and 15.2%, respectively. Irinotecan with carboplatin is effective for advanced NSCLC and safe.
References
Sep 15, 1990·Cancer Research·F KanzawaN Saijo
Mar 1, 1989·Journal of Medicinal Chemistry·R P HertzbergW D Kingsbury
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A H CalvertE Wiltshaw
Sep 1, 1985·Cancer Treatment Reviews·W C Rose, J E Schurig
Apr 19, 1995·Journal of the National Cancer Institute·E ChatelutR Bugat
Feb 1, 1993·Leukemia Research·Y KanoM Yoshida
Sep 1, 1996·Critical Reviews in Oncology/hematology·N MasudaM Fukuoka
Jun 1, 1997·Chest·C F Mountain, C M Dresler
Oct 7, 1997·Clinical Pharmacokinetics·S B Duffull, B A Robinson
May 30, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Lokich, N Anderson
Jul 31, 1998·British Journal of Cancer·N MasudaH Niitani
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F DeVoreL L Miller
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K KellyD R Gandara
Jul 4, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M OkaS Kohno
Jan 11, 2002·The New England Journal of Medicine·Kazumasa NodaUNKNOWN Japan Clinical Oncology Group
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Feb 15, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Nasser HannaAlan Sandler
Jul 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Minoru TakadaNagahiro Saijo
Oct 12, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M OkaS Kohno
Nov 26, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Koji TakedaShunichi Negoro
Feb 6, 2003·British Journal of Cancer·S NegoroUNKNOWN CPT-11 Lung Cancer Study Group West
Mar 1, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Filippo De MarinisUNKNOWN Foundation for Oncological Research
Jun 27, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yoshihiko SegawaUNKNOWN Okayama Lung Cancer Study Group
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin J EdelmanDavid R Gandara
Jul 6, 2004·International Journal of Radiation Oncology, Biology, Physics·Steven E SchildJames R Jett
Aug 25, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katsuyuki HottaMitsune Tanimoto
Jun 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harvey B NiellUNKNOWN Cancer and Leukemia Group
Citations
Feb 8, 2006·Cancer Chemotherapy and Pharmacology·Minoru FukudaMikio Oka
Feb 18, 2009·Cancer Chemotherapy and Pharmacology·Myung Hee ChangKeunchil Park
Apr 10, 2013·Cancer Chemotherapy and Pharmacology·Hyeong Su KimDae Ro Choi
May 9, 2008·Marine Drugs·Tom TurkKristina Sepcić
Feb 11, 2016·Asia-Pacific Journal of Clinical Oncology·Masashi TakanoYuh Sakata
Jan 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nicholas W ChoongAnn M Mauer
Jan 24, 2012·Clinical Lung Cancer·Hiroshi TakataniShigeru Kohno
Dec 18, 2015·BMC Cancer·Xue-Qin YangDong Wang
Apr 22, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chia-Hsuin ChangK Arnold Chan
Jun 10, 2011·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Minh-Tâm BaylatryAlex Laurent
Aug 23, 2005·Cancer Chemotherapy and Biological Response Modifiers·Max KreditorHoward S Hochster
Jun 7, 2005·Expert Opinion on Therapeutic Targets·Ladislav Novotny, Thomas Szekeres
Apr 20, 2006·British Journal of Cancer·A KinoshitaUNKNOWN Nagasaki Thoracic Oncology Group (NTOG)
Dec 6, 2014·Hospital Pharmacy·Matthew R RutledgeDominic A Solimando
Dec 14, 2018·Future Oncology·Shweta LawaniaSiddharth Sharma